Your browser doesn't support javascript.
loading
Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration.
Boyle, Rory; Townsend, Diana L; Klinger, Hannah M; Scanlon, Catherine E; Yuan, Ziwen; Coughlan, Gillian T; Seto, Mabel; Shirzadi, Zahra; Yau, Wai-Ying Wendy; Jutten, Roos J; Schneider, Christoph; Farrell, Michelle E; Hanseeuw, Bernard J; Mormino, Elizabeth C; Yang, Hyun-Sik; Papp, Kathryn V; Amariglio, Rebecca E; Jacobs, Heidi I L; Price, Julie C; Chhatwal, Jasmeer P; Schultz, Aaron P; Properzi, Michael J; Rentz, Dorene M; Johnson, Keith A; Sperling, Reisa A; Hohman, Timothy J; Donohue, Michael C; Buckley, Rachel F.
Affiliation
  • Boyle R; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Townsend DL; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Klinger HM; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Scanlon CE; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Yuan Z; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Coughlan GT; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Seto M; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Shirzadi Z; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Yau WW; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Jutten RJ; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Schneider C; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Farrell ME; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Hanseeuw BJ; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Mormino EC; Department of Neurology, Institute of Neuroscience, Cliniques Universitaires SaintLuc, Université Catholique de Louvain, Brussels, Belgium.
  • Yang HS; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
  • Papp KV; Wu Tsai Neuroscience Institute, Stanford, CA, USA.
  • Amariglio RE; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Jacobs HIL; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Price JC; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Chhatwal JP; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Schultz AP; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Properzi MJ; Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, The Netherlands.
  • Rentz DM; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Johnson KA; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Sperling RA; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Hohman TJ; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Donohue MC; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Buckley RF; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Alzheimers Res Ther ; 16(1): 148, 2024 07 03.
Article in En | MEDLINE | ID: mdl-38961512
ABSTRACT

BACKGROUND:

Leveraging Alzheimer's disease (AD) imaging biomarkers and longitudinal cognitive data may allow us to establish evidence of cognitive resilience (CR) to AD pathology in-vivo. Here, we applied latent class mixture modeling, adjusting for sex, baseline age, and neuroimaging biomarkers of amyloid, tau and neurodegeneration, to a sample of cognitively unimpaired older adults to identify longitudinal trajectories of CR.

METHODS:

We identified 200 Harvard Aging Brain Study (HABS) participants (mean age = 71.89 years, SD = 9.41 years, 59% women) who were cognitively unimpaired at baseline with 2 or more timepoints of cognitive assessment following a single amyloid-PET, tau-PET and structural MRI. We examined latent class mixture models with longitudinal cognition as the dependent variable and time from baseline, baseline age, sex, neocortical Aß, entorhinal tau, and adjusted hippocampal volume as independent variables. We then examined group differences in CR-related factors across the identified subgroups from a favored model. Finally, we applied our favored model to a dataset from the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 160, mean age = 73.9 years, SD = 7.6 years, 60% women).

RESULTS:

The favored model identified 3 latent subgroups, which we labelled as Normal (71% of HABS sample), Resilient (22.5%) and Declining (6.5%) subgroups. The Resilient subgroup exhibited higher baseline cognitive performance and a stable cognitive slope. They were differentiated from other groups by higher levels of verbal intelligence and past cognitive activity. In ADNI, this model identified a larger Normal subgroup (88.1%), a smaller Resilient subgroup (6.3%) and a Declining group (5.6%) with a lower cognitive baseline.

CONCLUSION:

These findings demonstrate the value of data-driven approaches to identify longitudinal CR groups in preclinical AD. With such an approach, we identified a CR subgroup who reflected expected characteristics based on previous literature, higher levels of verbal intelligence and past cognitive activity.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Magnetic Resonance Imaging / Tau Proteins / Positron-Emission Tomography Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Alzheimers Res Ther Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Magnetic Resonance Imaging / Tau Proteins / Positron-Emission Tomography Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Alzheimers Res Ther Year: 2024 Document type: Article